Skip to content
Brand AI

Hansen Pharmaceutical

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2021

    Actual Controller's Off-Book Advance of RMB 15.64 Million in Sales Expenses Leads to Hunan CSRC Rectification Order

    From 2017 to 2019, Hansen Pharmaceutical's actual controller, Liu Ling'an, used a personal account to advance sales expenses off the books for subsidiary Yongzitang, affecting net profit by about RMB 15.6419 million. In August 2021, the Hunan Securities Regulatory Bureau ordered the company to rectify the matter and issued warning letters to Liu Ling'an, Xinjiang Hansen Equity Investment, and directors Liu Zhengqing and Fu Jianjun; media questioned whether the company was window-dressing performance. Rectification order; warning letters.

    Source